Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Fimasartan, a selective angiotensin II type 1 receptor blocker, was approved in Korea for the treatment of patients with mild to moderate hypertension.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Ther

Title: Clinical therapeutics

Publisher: Elsevier BV

ISSN (Electronic): 1879-114X

ISSN (Print): 0149-2918

Publication date (Electronic): Sep 2013

Volume: 35

Issue: 9

Affiliations

[1 ] Center for Drug Development Science, Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California San Francisco, San Francisco, California, and University of California Washington Center, Washington, DC.

Article

Publisher Item ID: S0149-2918(13)00349-4

DOI: 10.1016/j.clinthera.2013.06.021

PubMed ID: 23932463

SO-VID: a97cce5b-4e03-4337-9243-17c973464043

History

Keywords: 24-hour ambulatory blood pressure monitoring,essential hypertension,fimasartan,valsartan,angiotensin receptor blocker

Data availability:

Keywords: 24-hour ambulatory blood pressure monitoring, essential hypertension, fimasartan, valsartan, angiotensin receptor blocker

Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.

Read this article at

Abstract

Related collections

Active Travel Studies

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 14